Cancer never crossed my mind. I thought it was a nasty infection they’d cut away.

Stereotaxis (NYSE:STXS) today announced the first patients successfully treated in the U.S. with its MAGiC system.

Good afternoon, and thank you for joining us. For those of you that are new to the Pulse Biosciences story, let me start with a brief overview of the technology at the core of everything we do. Pulse ...

U.S. District Judge David Campbell of the District of Arizona is overseeing the trial, which began on April 21 and is set to ...

Our top priorities are initiating commercialization of the percutaneous electrode for soft tissue ablation in benign thyroid ...

Matilda Garrett was a physical presence in defence, staying on the body of Fever’s Sasha Glasgow, but it was a collision down ...

Cardiac catheterization, a key diagnostic and treatment tool for heart disease since the mid-20th century, has evolved with advances in technology, patient preparation, and recovery protocols. Modern ...

Electroanatomical mapping results from the three months follow-up on 34 patients were presented at the European Heart Rhythm Association 2026 showing 94% durable and consistent pulmonary vein ...

A new study shares the results of a clinical trial into the use of a catheter coated with a bacteria-resistant material. The ...

Stereotaxis has completed the first U.S. procedures using its FDA‑approved MAGiC robotic magnetic ablation catheter, designed for complex congenital heart disease cases where traditional approaches ...

The first time the company’s MAGiC catheter was used in the U.S., it did not ease into things gently. On April 22, 2026, ...